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MCR, multicomponent reaction; 
FP, fluorescence polarization; 
MDM2, murine double minute-2; 
MDMX, murine double minute-X; 
RMSD, root mean square deviation; 
FBS, fetal bovine serum; 
DMSO, dimethyl sulfoxide; 
PVDF, polyvinylidene fluoride; 
BSA, bovine serum albumin; 
TBS, Tris-buffered saline; 
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
MTT, 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide; 
PBS, phosphate-buffered saline; 
FITC, fluorescein isothiocyanate; 
DTT, dithiothreitol; 
IPTG, isopropyl β-D-1-thiogalactopyranoside; 
MME, monomethyl ether; 
PEG, polyethylene glycol; 
NMR, nuclear magnetic resonance spectroscopy; 
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ABSTRACT 
The p53 protein is engaged in the repair of DNA mutations and elimination of heavily damaged 
cells, providing anti-cancer protection. Dysregulation of p53 activity is a crucial step in carcinogenesis. 
This dysregulation is often caused by the overexpression of negative regulators of p53, among which 
MDM2 is the most prominent one. Antagonizing MDM2 with small molecules restores the activity of 
p53 in p53 wild-type (p53
wt




Previously, we have reported the discovery of a panel of fluoro-substituted indole-based 
antagonists of MDM2. Here, we demonstrate the biological activity and stereoselectivity of the most 
active compound from this series. Both enantiomers of the esterified form of the compound, as well as 
its corresponding carboxylic acids, were found active in fluorescence polarization (FP) assay, nuclear 
magnetic resonance (NMR) and microscale thermophoresis (MST) assay, with Ki and KD values 
around 1 µM. From these four compounds, the esterified enantiomer (R)-5a was active in cells, which 
was evidenced by the increase of p53 levels, the induced expression of p53-target genes (CDKN1A 
and MDM2), the selective induction of cell cycle arrest and selective growth inhibition of p53
wt
 U-2 OS 
and SJSA-1 compared to p53
del
 SAOS-2 cells. The analysis of the crystal structure of human MDM2 
in complex with the compound (R)-6a (carboxylic acid of the active (R)-5a compound) revealed the 
classical three-finger binding mode. Altogether, our data demonstrate the activity of the compound 
and provide the structural basis for further structure optimization. 
 
INTRODUCTION  
The protein p53 is a well-known tumor suppressor, activated in a response to several different 
stimuli, including DNA damage. Due to its tumor-suppressive activity, p53 is dysregulated in almost 
every single cancer [1]. It is estimated that 50% of cancers inactivate p53 by gaining loss-of-function 
mutations or deletions in the TP53 gene [2]. The remaining 50% of cancers utilize natural 
mechanisms of negative regulation of p53, enhanced to the extent that disallows its activation. In this 
regard, the increase of the inhibitory potential of MDM2 protein is the most common way to keep p53 
inactive. MDM2 has the ability to inhibit p53 in the two different ways: by masking the transactivation 
domain of p53 and by directly ubiquitinating p53, directing the protein to proteasomal degradation [3]. 
The gene encoding MDM2 protein is very frequently amplified in human cancers, leading to MDM2 
overexpression [3]. Overexpressed MDM2 bind to p53, leading to the permanent inactivation of this 
protein. Accordingly, forced disruption of p53/MDM2 complexes became a favored strategy of the 
restoration of p53 functioning in p53
wt
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Over the last years, numerous small molecule scaffolds have been proposed, that are able to 
disrupt the MDM2/p53 complexes. Among these compounds, several presented truly promising 
preclinical results and are currently undergoing clinical trials [5]. This includes small molecule 
derivatives of nutlin-3, RG7112 and RG7388 from Roche [6,7], the successor of AM-8553 compound, 
AMG 232 from Amgen [8], CGM097 and HDM201 from Novartis [9], and spiro-oxindole compounds, 
SAR405838 (MI-77301) from Sanofi [10], DS-3032b from Daiichi Sankyo [11] and APG-115 from 
Ascentage Pharma Group [12]. Moreover, several stapled peptides have been described with high 
affinity toward MDM2 and MDMX, with representative molecule, ALRN-6924 (Aileron Therapeutics), 
currently undergoing phase I and II clinical trials in patients suffering from solid tumors, lymphoma 
and myeloid leukemias [5]. 
 
In recent years, we have successfully designed and synthesized MDM2 antagonists based on the 
well-recognized three-point binding model using a pharmacophore-based screening approach and 
multi-component reaction chemistry [13–21]. Among these reports, we have reported the design, 
synthesis, and activity of a library of MDM2 antagonists, substituted with fluorine at various positions 
and synthesized by a classical Ugi four-component reaction (U-4CR) [22]. We showed that the 
introduction of fluorine substituents to the benzyl group can considerably improve the in vitro MDM2 
binding activity of the antagonists due to the electrostatic interaction between small molecules and the 
His96 residue of the protein. We have then identified the most active compound, which was able to 
the p53/MDM2 interaction with Ki values of 0.13 µM and 0.4 µM for the corresponding acid and ester 
form, respectively [22]. In the current report, we demonstrate the biological activity of our most potent 
trifluoro-substituted compound in comparison to known MDM2 antagonists nutlin-3a and Idasanutlin 
(RG7388). In addition, we report the structural basis of the interaction of our compound (de-esterified) 
with human MDM2 protein for further structure-based optimization of its properties. 
 
RESULTS 
The synthesis of the compounds 
Based on our previous work [22], we resynthesized and scaled-up the most promising trifluoro-
substituted compound (Figure 1) for further evaluation of its activity employing biochemical, 
biophysical and cellular assays. The synthesis involves a convergent Ugi 4-component reaction and 
the MDM2 antagonists can be assembled in just 2 steps from commercially available starting 
materials [22]. The equimolar mixing of the 3,4,5-trifluorobenzylamine (1), the indole-3-
carboxaldehyde (2), tert-butyl isocyanide (3) and formic acid (4) led to the desired p53-MDM2 
antagonist (5) (for the detailed description of synthetic procedures and analytical data see Supporting 
Information (SI)). The resulting racemic mixture was subjected to preparative chiral separation 
yielding the two enantiomers, (R)-5a and (S)-5b (see the section 1.5 of SI, Figure S1 and Table S1 for 
the details on the separation of enantiomers). The two latter compounds were hydrolyzed into the 
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The compounds 5 and 6 bind to MDM2  





N HSQC NMR and microscale thermophoresis (MST) were used to test the in 
vitro activity of the compounds. The FP assay was performed to compare the MDM2-p53 inhibitory 
activity of new batches of the compounds with the data reported in our previous study [22]. The assay 
was performed for the enantiomers R of the compounds (5) and (6), as these enantiomers presented 
higher activity in our previous study [22]. Both compounds presented Ki values much lower than 1 μM, 





N HSQC NMR titration was used to verify the results of the FP assay. This method is based 
on monitoring the chemical shift changes in protein amide backbone resonances upon protein 
interaction with a small molecule [23–25]. The binding to MDM2 protein was confirmed for all the final 
compounds, i.e. (R)-5a, (S)-5b, (R)-6a and (S)-6b. The pattern of chemical shift changes observed for 
the compound (R)-6a was similar to the pattern reported in our previous work and also correlates well 
with the FP data [22]. Tight binding, characterized by the slow chemical exchange and observed as 
doubling of NMR signals [26] was noted for the compounds (R)-5a, (R)-6a and (S)-6b (Figure 2, 
Figure  S2 and Figure S3). Such a behavior is characteristic for the compounds with dissociation 
constants KD values below 1 μM. NMR results showed that acids (R)-6a and (S)-6b were more potent 
compared to their esters (R)-5a and (S)-5b (Table 1). This was most evident for the compounds (S)-
5b/6b, for which only acid (S)-6b, but not the ester (S)-5b, was able to evoke peaks doubling (Figure 
S4). For (S)-5b, though, the spectrum is characteristic for intermediate chemical exchange range 
which is indicated by broadening and disappearing of peaks like Gly58 or Gly12. For the compounds 
that undergo intermediate chemical exchange, it is feasible to determine the KD value [27,28]. The 
calculated KD for (S)-5b was 10.7±6.5 μM (Figure S4). The comparison of enantiomers shows that 
from the pair of the ester compounds (R/S)-5a/b the R-enantiomer is far more potent than the S-
enantiomer. In the case of acids (R/S)-6a/b, both enantiomers exhibit similar potency in the tested 
system. 
 
Finally, a third assay, microscale thermophoresis (MST) was employed to cross-validate the 
binding affinity of tested compounds. The technique relies on the thermophoretic motion of the 
molecule in a temperature gradient induced by a high precision IR-laser beam. Changes in the 
molecular diffusion resulting from binding events provide information on affinity [29,30]. 
 
In the experimental setup, the concentration of a fluorescently labeled MDM2 was fixed at 100 
nM, whereas the concentration of an unlabeled binding compound was varied. All the tested 
compounds showed an affinity towards MDM2 in the low µM range (Table 1, raw data available in the 
SI file). The KD values were 7.0 µM and 1.3 µM for the (R)-6a and (S)-6b enantiomers, respectively. 
Likewise, the binding of ester enantiomers, (R)-5a and (S)-5b to the fluorescently labeled MDM2 led 
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The compounds 5 and 6 disrupt the MDM2-p53 complex  
As described above, the compounds 5 and 6 bind to MDM2 and are able to displace p53-derived 
peptide complexed with MDM2 protein. To verify if the compounds are also able to dissociate the p53-
MDM2 complex, the compounds were tested by the Antagonist Induced Dissociation Assay (AIDA-
NMR) [31].  
 
The method is based on the NMR spectroscopy of the complex formed by the human p53 
(residues 1-321) and human MDM2 (residues 1-125), and its subsequent dissociation upon the 
titration with the inhibitor. Usually the methodology is performed using 
15
N labeled protein. However, if 
the distinguished, well separated peaks are observed in 
1
H spectra, it is feasible to perform the AIDA-
NMR with unlabeled proteins. The analyzed p53-MDM2 complex have the required characteristic 




 indole residues of 
Trp23, Trp53 and Trp91. Therefore, we decided to perform a proton AIDA-NMR experiments for all 
the compounds with FP Ki values below 1 μM, and defined as ‘tight binders’ by the NMR 
spectroscopy, i.e. the compounds (R)-5a, (R)-6a and (S)-6b), along with a known MDM2 antagonist, 
nutlin-3a as an reference. 
 
On the 1D proton spectrum of the reference p53-MDM2 complex shows only two peaks, 
corresponding to Trp91 and Trp53 of p53 (Figure S5). The peak corresponding to the Trp23 is not 
visible, because this residue is buried inside the protein complex, as it participates in the complex 
formation. The residues Trp53 and Trp91 are accessible for NMR spectroscopy even when p53 is 
bound to MDM2 and their corresponding signals are not expected to vary between MDM2-bound and 
unbound p53. Upon the titration of the complex with MDM2 antagonists, the formation of the peak 
originating from Trp23 is observed, as exemplified for nutlin-3a (Figure S5 A). This indicates the 
release of p53 from its complex with MDM2. The p53-MDM2 complex titrated with each of the tested 
compounds resulted in similar observations, suggesting that the compounds are indeed disrupt p53-
MDM2 complex in solution (Figure S5 B-D). 
 
(R)-6a binds to MDM2 with a classical three-finger binding mode 
To characterize the structural basis of the interactions of the evaluated compounds at the 
hydrophobic pocket of the p53-binding domain of MDM2, we determined the crystal structure of (R)-
6a in complex with MDM2(18-125) (fragment of MDM2 comprising residues 18-125). The compound 
(R)-6a was chosen as the most potent one in the FP assay. The obtained crystals diffracted to 2.0 Å 
resolution and contained one protein-inhibitor complex in the asymmetric unit, with (R)-6a well defined 
by its electron density (Figure S6) and with no additional inhibitor molecules found within the structure 
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(R)-6a binds to MDM2 with a classical three-finger binding mode (Figure 3A,B), occupying all 
three p53-binding subpockets defined by following residues of p53: Phe19, Trp23, and Leu26 (Figure 
3C). Concerning the similarities to the native interaction, the binding of (R)-6a into the cleft of MDM2 
is primarily stabilized by hydrophobic interactions with Leu54, Leu57, Gly58, Ile61, Met62, Tyr67, 
Val75, Phe86, Phe91, Val93, Ile99, Tyr100 and Ile103 (residues labeled at Figure 4A). Another 
resemblance is noticed for the 6-chloroindole substituent of (R)-6a that inserts into a Trp23 subpocket 
and assumes an orientation almost identical to the Trp side chain of p53 in the native p53−MDM2 
complex. The chlorine atom introduced in (R)-6a stabilizes the interaction at the bottom of the 
hydrophobic cleft. Such an arrangement of 6-chloroindole moiety repeating the p53’s Trp23 indole 
interaction follows a canonical binding observed in many different classes of MDM2 inhibitors [32]. 
Further, comparable to p53 interaction, the NH group within 6-chloroindole participates in a hydrogen 
bond with the carbonyl oxygen of Leu54 (length of 2.6 Å, Figure 4A). 
 
Concerning the remaining MDM2 subpockets which are naturally occupied by p53’s Phe19 and 
Leu26, the differences can be easily spotted as the character (alkyl/aryl) of substituents of (R)-6a 
differs from p53’s side chains. The Phe19 subpocket accommodates the tert-butyl substituent of (R)-
6a directed at Tyr67. The 3,4,5-trifluorobenzyl substituent of (R)-6a fills the Leu26 subpocket pointing 
towards Tyr100 and is involved in π-stacking with His-96 side chain (Figure 4A) [22]. Moreover, this 
stacking results also in the change of the overall shape of Leu26 subpocket when compared to the 
native interaction, as in case of (R)-6a  it gets ‘closed’ and less exposed to the solvent. 
 
Additionally, the inhibitor’s scaffold and carboxylic group of (R)-6a further contribute to the 
formation of several hydrogen bonds with water molecules interacting with MDM2 (Figure 4B). Taken 
together, hydrophobic interactions, hydrogen bonds and π-stacking define the high affinity of (R)-6a to 
p53-binding pocket of MDM2. 
 
The MDM2 antagonist (R)-5a activates p53 and induces the expression of p53-dependent 
genes 
The disruption of the p53/MDM2 interaction in p53
wt
 cells leads to the release of transcriptionally 
active p53, which then regulates the expression of a panel of target genes. The protein p21 is a 
product of such a well-known p53-regulated gene and changes in its expression are often examined 
to track the activation of p53. 
 
To test the bioactivity of the compounds, human osteosarcoma U-2 OS cells were treated with 
increasing concentrations of the compounds (R)-5a and (R)-6a for 24 hours, followed by western blot 
analysis of the expression of p21 protein. As a control, two MDM2 antagonists were used: Nutlin-3 
and RG7388 as one of the best-studied compounds and one of the most potent antagonists, 
respectively. Both compounds increased the expression of p21 and p53 in U-2 OS cells (Figure 5A). 
The compound (R)-5a induced a strong expression of both p53 and p21 protein, proving the efficient 
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concentrations of 5 and 10 µM of the compound. The carboxylic acid version of (R)-5a, compound 
(R)-6a, did not alter the expression of the examined proteins (Figure 5A).  
 
To check the stereo-selectivity of the compound 5 in living cells, both enantiomers of the 
compound (5), (R)-5a and (S)-5b, were tested in a western blot experiment. The analysis confirmed a 
strong activity of (R)-5a, while the enantiomer (S)-5b was found inactive (Figure 5B). This 
corresponded well with the FP, NMR and MST results, where the enantiomer S was found less active 
than the R enantiomer (Table 1). 
 
While the increase of p53 protein levels in response to MDM2 antagonists is due to increased 
stability of the p53 protein, the increase of expression of p53 targets, p21 and MDM2, is related to 
transcriptional induction of CDKN1A and MDM2 genes, respectively. To verify if the increased protein 
levels are associated with increase abundance of corresponding transcript a real-time PCR was 
performed with the detection of MDM2, CDKN1A and TP53 transcripts. The results clearly show that 
the treatment of U-2 OS cells with MDM2 antagonists, RG7388 or (R)-5a, leads to a significant 
increase of MDM2 and CDKN1A transcripts (Figure 5C). This suggest that the (R)-5a compound 
indeed indices transcriptional activity of p53 in living cells. 
The compound (R)-5a selectively inhibits the growth of p53
wt
 cells 
To evaluate the selectivity of (R)-5a towards p53
wt
 cells, a cell viability MTT assay was performed 
on two p53
wt
 cell lines, U-2 OS and SJSA-1, and one p53
del
 cell line, namely SAOS-2. Both p53
wt
 cells 
were more susceptible to (R)-5a than SAOS-2 cells with the resulting IC50 values of 3.3 µM and 2.7 
µM for U-2 OS and SJSA-1 cells, respectively, and 13.6 µM for SAOS-2 cells (Figure 5D). 
 
The anticancer activity of MDM2 antagonists results mainly from the induction of cell cycle arrest 
[33]. To analyze the induction of cell cycle arrest by (R)-5a flow cytometry analysis was performed. A 
positive control compound RG7388 decreased the percentage of S-phase cells from 55% to 0.5% in 
U-2 OS cells at the concentration of 5 µM (Figure 5D). Similarly, (R)-5a induced cell cycle arrest as 
demonstrated by the decrease of the percentage of S-phase cells from 55% to 16% and 1.4% at the 
concentrations of 5 and 10 µM, respectively (Figure 5D). Even stronger cell cycle arrest was observed 
for SJSA-1 cells, that are known to be extremally sensitive to MDM2 antagonists, but no effect was 
noted for p53
del
 SAOS-2 cells supporting the activity and selectivity of the compound (Figure S7). 
 
The compound (R)-5a induces apoptosis in p53
wt
 SJSA-1 cells 
The activation of p53 with the use of MDM2 antagonists leads not only to the growth inhibition of 
p53
wt
 cells, but also to the induction of apoptosis, although this effect is restricted to a sub-group of 
p53
wt
 cells [33–36]. To verify the pro-apoptotic properties of the MDM2 antagonist (R)-5a a caspase 
3/7 activity assay was performed with the use of U-2 OS and SJSA-1 osteosarcoma cells. The cells 
were treated with staurosporine (positive control), RG7388 (potent MDM2 antagonist), (R)-5a (active 
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induced apoptosis in both cell lines. The active (R)-5a compound showed the activity similar to 
RG7388 – it induced apoptosis only in SJSA-1 cells, and not in U-2 OS cells. Although both cell lines 
possess wild type p53 protein, SJSA-1 is known to be highly susceptible to apoptosis induced by 
MDM2 antagonists [33]. Altogether, the results suggest that the compound (R)-5a presents the 
bioactivity characteristic for other, well known MDM2 antagonists. 
 
DISCUSSION 
In previous studies, we have reported new scaffolds for the design and optimization of MDM2 
antagonists, synthesized in one-step multicomponent reactions. We have also performed an 
exhaustive scanning of fluorine substitutions at the phenyl group of the indole-based compound and 
provided the proof of the optimized properties of some of the resulting fluoro-substituted compounds. 
Here, we investigated in detail the strongest MDM2 binder from the previous series. By using three 
different biophysical techniques we observed strong MDM2 binding of all four final compounds. In 
accordance with the binding studies, the (R)-5a enantiomer showed concentration-dependent 
upregulation of p21 and growth inhibition in different p53 wild-type cell lines. Moreover, the compound 
showed induction of cell cycle arrest in different wild-type p53 cell lines in low µM concentrations, 
comparable to the clinical compound RG7388. In contrast, the less-binding (S)-5a enantiomer was not 
bioactive in vitro. Similarly, the non-esterified compound (R)-6a had no activity in cells, suggesting 
that the esterification is necessary for obtaining the biological activity. This may be for example due to 
increased cell permeability or compound stability. 
 
Currently, several second and third generation MDM2 antagonists are available, with some 
prominent examples that have entered clinical trials and are evaluated for the treatment of cancer 
patients [5]. The compound (R)-5a, presented in this manuscript shows a decent and promising in 
vitro activity, including reactivation of p53 in p53
wt
 cancer cells. However, the structure of the 
compound would require further development before entering in vivo examination, as its activity is 
revealed at relatively high concentrations (above 1 µM). The crystal structure of (R)-6a, the de-
esterified counterpart of the (R)-5a compound, bound to MDM2 protein may help in planning of further 
structure optimization steps. Our recent work suggests that further extending of the compound 
residue substituents leads to the forced opening of a fourth binding pocket, which, along with the 
classical Phe19, Trp23, and Leu26 binding pockets, may facilitate the interaction and potentiate the 
MDM2-antagonizing properties of the compound [13]. For sure the great advantage of the MDM2 
antagonist (R)-5a described in this manuscript lies in its synthesis process, which leads to the 
generation of a complex chemical entity in a one step, four component Ugi reaction. The structure of 
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MATERIALS AND METHODS 
Protein Expression and Purification  
Fragments of human MDM2 (residues: 1-118 in pET46; 18-125 - in pET20) were expressed in the 
Escherichia coli BL21-CodonPlus (DE3) RIL strain. Cells were cultured in a total volume of 5 l of LB or 
minimal medium at 37°C and induced with 1 mM IPTG at OD600nm of 0.8. Protein was expressed for 5 
h at 37°C. Cells were collected by centrifugation (20 min, 5000∙g), resuspended in 120 ml PBS with 
protease inhibitor cocktail and lysed by sonication. Inclusion bodies that were collected by 
centrifugation (30 min, 18000∙g), washed twice with 120 ml PBS containing 0.05% Triton-X100 and 
once with 120 ml PBS and centrifuged (15 min, 15000∙g) after each wash. Purified inclusion bodies 
were solubilized in 20 ml of 6 M guanidine hydrochloride in 100 mM Tris-HCl, pH 8.0, containing 1 
mM EDTA and 10 mM β-mercaptoethanol. The protein was dialyzed against 1 l of 4 M guanidine 
hydrochloride, pH 3.5 supplemented with 10 mM β-mercaptoethanol. Following, the protein was 
refolded by dropwise addition into 1 l of 10 mM Tris-HCl, pH 7.0, containing 1 mM EDTA and 10 mM 
β-mercaptoethanol and slow mixing overnight at 4°C. Ammonium sulfate was added to the final 
concentration of 1.5 M, mixed for 2 h and centrifuged for 40 min at 10000∙g. The refolded protein was 
recovered on Butyl Sepharose 4 Fast Flow previously equilibrated with refolding buffer containing 1.5 
M (NH4)2SO4. The column was washed and the protein was eluted using 100 mM Tris-HCl, pH 7.2, 
containing 5 mM β-mercaptoethanol. Fractions containing the protein were pooled and purified by gel 
filtration on S75 16/600 column in 5 mM Tris-HCl pH 8.0 containing 50 mM NaCl and 5 mM β-
mercaptoethanol (crystallization buffer) or in 50 mM phosphate buffer pH 7.4 containing 150 mM NaCl 
and 5 mM DTT (FP/NMR buffer). 
 
MDM2-p53 complex expression and purification for the AIDA-NMR 
Human MDM2-p53 complex (residues: 1-125 of Mdm2 with poly-histidine tag; 1-321 of p53 in 
pETDuet-1) were expressed in the Escherichia coli BL21-CodonPlus (DE3) RIL strain. Cells were 
cultured in a total volume of 4 L of LB and induced with 0.5 mM IPTG at OD600nm of 0.7. Protein was 
expressed for 16 h at 20°C. Cells were collected by centrifugation (20 min, 5000 g), resuspended in 
140 ml of 50 mM monosodium phosphate buffer pH 8.0, containing 300 mM sodium chloride and 10 
mM imidazole and lysed by sonication. Soluble protein complexes were recovered on Ni-NTA resign 
previously equilibrated with resuspension buffer. The column was washed with 50 mM monosodium 
phosphate, pH 8.0, containing 300 mM sodium chloride and 20 mM imidazole and the protein was 
eluted using 50 mM monosodium phosphate, pH 8.0, including 300 mM sodium chloride and 250 mM 
imidazole. Fractions containing the complex were pooled and purified by gel filtration on S200 16/60 
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Fluorescence Polarization Assay 
Fluorescence Polarisation (FP) assay was used to monitor interactions between MDM2 and its 
antagonists. For each assay, fresh protein stocks of MDM2 (1-118) were thawed and the protein 
concentrations were determined using the Bradford method. Assay buffer contained 50 mM NaCl, 10 
mM Tris pH 8.0, 1 mM EDTA and 5 % DMSO. All the experiments were prepared in duplicates. 
The binding affinity of the mutant p53 peptide (P2 peptide, sequence: LTFEHYWAQLTS, labeled 
with carboxyfluorescein) towards MDM2 was first determined. For this purpose, 10 nM of the 
fluorescent P2 peptide was contacted with serial dilutions of tested protein (range from 750 
to 0.012 nM) in a final volume of 100 μl and fluorescence polarization was determined. KD was 
determined by fitting the curve described by below equation to experimental data: 
(I)          
               
    
 
where FP is the determined value of fluorescence polarization, FPmin- fluorescence polarization for 
ligand only, FPmax- fluorescence polarization at protein concentration saturating the ligand, and c – 
protein concentration. Competition binding assay was performed using 10 nM fluorescent P2 peptide 
and optimal protein concentration for the measurement calculated based on determined KD according 
to Huang, 2003 (f0 = 0.8) [37]. Tested compounds were dissolved in DMSO at 50 µM. Serial dilutions 
(50 μM to 0.05 μM) were prepared in DMSO. Nutlin-3a was used as positive controls for MDM2. 
Fluorescence polarization was determined using Tecan InfinitePro F200 plate reader with the 485 nm 
excitation and 535 nm emission filters. The fluorescence intensities, parallel and perpendicular to the 
plane of excitation, were determined in Corning black 96-well NBS assay plates at room temperature. 
Fluorescence polarization values were expressed in millipolarization units (mP). Inhibition curves 





N isotope labeling was achieved by the expression of Mdm2 (residues 1-118) protein in 
the M9 minimal media containing 
15
NH4Cl as the sole nitrogen source. The final step of purification of 
Mdm2 for NMR consisted of gel filtration into the NMR buffer (50 mM phosphate buffer pH 7.4 
containing 150 mM NaCl, 5 mM DTT). 10% (v/v) of D2O was added to the samples to provide lock 
signal. Water suppression was carried out using the WATERGATE sequence [38]. All the spectra 





heteronuclear correlations were obtained using the fast HSQC pulse sequence [39]. Assignment of 
the amide groups of Mdm2 was obtained after Stoll et al [40]. 
 




N correlated NMR spectrum was recorded at 7-9 
different ligand/protein ratios, ranging from 0:1 to 5:1. The samples were prepared by adding small 
amounts of a 50 mM ligand stock solution in DMSO to the protein solution (0.2 ml) containing the 
15
N 
labeled Mdm2 fragment at a concentration of 0.16 – 0.30 mM. The acquisition parameters for each 
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Spectra were visualized using TopSpin 4.0.2. For the determination of dissociation constants (KD), 
nonlinear fits of chemical shifts of single residue versus ligand ratio were performed using the 
program OriginPro (version 9.1) according to the following equation:
  
 
(II)        
                              
           
     
 
Where  
[L]0 – ligand concentration  
[P]0 – protein concentration 
Δobs – observed chemical shift perturbation normalized according to the Pythagoras formula with 
15
N weighting factor of 0.2.  
δM –chemical shift for single residue obtained with maximum ligand concentration  
KD – dissociation constants  
The final value of KD was calculated as a weighted mean value of KD’s obtained for most 
perturbed residues which undergo fast chemical exchange: Val93, Ile74, and Tyr60. 
 
Microscale Thermophoresis (MST) 
Twenty micromolar of the purified human MDM2 protein (residues 1-118) was fluorescently 
labeled following NanoTemper’s Protein Labeling Kit RED-NHS protocol for N-hydroxysuccinimide 
(NHS) (L001- NanoTemper Technologies, Munich, Germany), coupling NT647 dye to lysine residues. 
The labeled protein was pretested in standard treated, hydrophilic, hydrophobic and premium-coated 
MST capillaries (NanoTemper Technology) for protein adsorption to the capillary wall; this was 
evaluated by capillary scans performed by Monolith NT.115 prior to MST experiments. 
 
For MST experiments, the concentration of the labeled MDM2 was kept constant at 100 nM while 
the unlabeled binding compounds were titrated in 1:1 ratio within 16 two-fold serial dilutions. The 
compounds stocks were prepared in DMSO (100 mM) and diluted into the assay MST optimized 
buffer (50 mM Tris-HCl buffer, pH 7.6 containing 150 mM NaCl, 10 mM MgCl2 and 0.05% Tween-20) 
to reach the final concentration of the assay. Four compounds were tested for binding affinity toward 
MDM2: 5a,b, and 6a,b. Each compound was titrated against a specific amount of MDM2 starting from 
the highest concentration of 1.25 mM for (R)-6a, (S)-6b and (R)-5a compounds containing 5% DMSO, 
except (S)-5a with 0.032 mM as starting highest concentration and 1.5% final DMSO concentration. 
For the subsequent measurements, serial dilutions were prepared, mixed with MDM2 solution of 200 
nM in a final volume of 20 µl and incubated for 4 min. Followed by loading of each reaction mixture 
into a capillary, placed on the sample tray and then finally transferred to the instrument. MST 
measurements were taken in Premium-coated capillaries (MO-K025, NanoTemper Technologies) on 
a Monolith NT.115 instrument using 40% MST power, an LED excitation source with = 625n at 22 
°C with laser off/on times of 5 s. NanoTemper MO. Affinity Analysis v2.2.4 software was used to fit the 
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Protein crystallization 
Human MDM2 was prepared in 5 mM Tris pH 8.0, 50 mM NaCl and 5 mM β-mercaptoethanol. 
Molar excess (3x) of the inhibitor (50 mM stock in DMSO) was added and the MDM2-inhibitor 
complex was concentrated to 20 mg/ml. Screening for crystallization conditions was performed using 
a sitting drop vapor diffusion method. Crystals of the MDM2-inhibitor complexes appeared after a few 
days at 4°C in 0.1 M Bis-Tris pH 6.5 containing 20% (w/v) PEG 5000 MME. MDM2 crystals were 
flash-cooled in liquid nitrogen without further cryoprotection. 
 
Data collection and crystal structure determination 
The diffraction data were collected at 14.1 beamline at the BESSY II, Berlin, Germany. The data 
was indexed and integrated using XDS [41]. The further computational steps were performed with 
programs contained in the CCP4 package [42] or Phenix [43]. The data was scaled and merged using 
Scala [44]. Initial phases for MDM2 structures were obtained by molecular replacement using Phaser 
[45] and MDM2 structure derived from PDB ID 3TJ2 (MDM2 18-125) as a search model. The models 
were manually built in the resulting electron density maps using Coot [46]. Restrained refinement was 
performed using Phenix [43]. After several cycles of model building and refinement, the electron 
densities defining the ligands in MDM2 structures became clearly visible and the ligand molecule was 
introduced into the model. The restrains defining the ligand molecule were prepared using JLigand 
[47]. Water molecules were added using Coot and subsequently manually inspected. The data 
collection and refinement statistics for all complexes are summarized in Table S2. The structure 
factors and final models were deposited into PDB with the following accession number: 5OAI. 
 
Cell lines-culture and treatment 
Human osteosarcoma cell lines U-2 OS (p53
wt
) and SAOS-2 (p53
del
) were purchased from 
ECACC (Sigma Aldrich) and cultured in McCoy's 5A Medium containing L-glutamine (Lonza) and 
supplemented with 10% fetal bovine serum (FBS, Biowest). Human osteosarcoma SJSA-1 (p53
wt
) cell 
line was purchased from ATCC (LGC Standards) and cultured in RPMI-1640 Medium containing L-
glutamine and supplemented with 10% FBS. The cells were cultured at 37°C and 5% CO2 in a 
humidified atmosphere and tested for Mycoplasma contamination using the PCR-based method [48]. 
All compounds were prepared as 50 mM stock solutions in DMSO. The compounds were further 
diluted in DMSO (working solutions, 0.2-20 mM) and added to the culture medium for the cell 
treatment. The final concentration of DMSO was kept constant and its final concentration was below 














This article is protected by copyright. All rights reserved. 
Western blot analysis 
U-2 OS cells (120 000 cells per well) were seeded on 12-well transparent plates (Falcon). On the 
next day, the compounds were added and the cells were cultured for an additional 24 h. Cells were 
lysed with RIPA buffer (Sigma Aldrich) supplemented with protease inhibitor cocktail (Sigma Aldrich). 
The protein lysates were clarified by centrifugation and analyzed on 12% SDS polyacrylamide gel 
(Bio-Rad). The proteins were transferred to PVDF membrane (Merck Millipore). The membranes were 
blocked for 1 h in 4% bovine serum albumin (BSA, Bioshop) in TBS-N buffer (150 mM NaCl, 20 mM 
Tris-HCl pH 7.6, containing 0.1% Nonidet). Membranes were probed with rabbit monoclonal anti-p21 
antibody (1:2000, Cell Signaling, cat. no. 2947) and rabbit monoclonal anti-GAPDH antibody (1:4000, 
Cell Signaling, cat. no. 2118). Anti-rabbit antibody conjugated with horseradish peroxidase (1:2000, 
Cell Signaling, cat. no. 7074) was used to detect the primary antibodies. The blots were developed 
with Clarity Western ECL Substrate (Bio-Rad) and visualized using ChemiDoc MP System (Bio-Rad). 
Densitometry analysis was performed using ImgeLab software (Bio-Rad). 
 
RNA isolation and real-time PCR 
For the isolation of RNA, 120 000 U-2 OS cells were seeded on 12-well plates (Falcon). The next 
day, the cells were treated for 6 hours with 5 µM RG7388, 10 µM (R)-5a or DMSO as a control. The 
total RNA was isolated and purified using PureLink RNA MiniKit (Invitrogen, Thermo Fisher Scientific) 
supplemented with PureLink DNase (Invitrogen, Thermo Fisher Scientific), according to the 
manufacturer's protocol. Subsequently, 1 µg of total RNA was used for reverse transcription, 
performed with the use of M-MLV Reverse Transcriptase (Promega) and oligo-dT primer. After the 
synthesis, cDNA was amplified in real-time PCR, as described in the manufacturer’s protocol, using 
TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific) with TaqMan Gene Expression Assays 
for the genes MDM2 (assay ID: Hs01066930_m1), TP53 (assay ID: Hs01034249_m1), CDKN1A 
(assay ID: Hs00355782_m1), and GAPDH (assay ID: Hs02758991_g1), which was used as a 
reference gene. The reaction was run on the Eppendorf Realplex 2 System. All samples were run in 
duplicates. The results were analyzed using the “ΔΔCt” relative quantitation method. 
 
Cell viability MTT assay 
U-2 OS cells (500 cells per well), SJSA-1 cells (1000 cells per well) and Saos-2 cells (1000 cells 
per well) were seeded on 96-well transparent plates (Falcon). Next day the cells were treated with the 
compounds, prepared at the final concentrations in the fresh culture medium, and cultured for 
additional 5 days. Thiazolyl blue tetrazolium bromide (MTT, Sigma Aldrich) was added at the final 
concentration of 0.5 mg/ml and the cells were incubated for 1 h at 37°C. The medium was carefully 
removed and formazan crystals were dissolved in isopropanol containing 40 mM HCl. The 
absorbance was measured with Infinite 200 microplate reader (Tecan Group Ltd.) at 570 nm with the 
reference wavelength 650 nm for background subtraction. Data was analyzed using Origin software 
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Cell cycle analysis 
U-2 OS cells were seeded at 300 000 per 60∙15 mm cell culture dish (Eppendorf), treated with 
tested inhibitors for 24 h, trypsinized and fixed with 70% ethanol. The cell concentration was adjusted 
to 1 x 106 cells/sample and DNA was labeled with PI-RNase solution (PBS, 5 g mL-1 propidium 
iodide, 0.01 mg mL-1 RNase A) for 30 min at 25°C. The cells analyzed for cell cycle DNA content 
using LSRFortessa cell analyzer (BD Biosciences). 
 
The cells were seeded on cell culture dishes (Eppendorf) and treated next day with DMSO 
(control), RG7388 or the compounds for additional 24 hours. During the last hour of the treatment, the 
cells were pulse-labeled with 10 mM bromodeoxyuridine (BrdU, Sigma Aldrich). After that, the cells 
were harvested by trypsinization and fixed with 96% ethanol in -20 °C for at least 24 hours. Following 
the fixation, 10
6
 cells were centrifuged and the supernatant was removed. Drop by drop, 1 ml of 2N 
HCl with Triton X-100 (0.5% v/v) was added while vortexing and the cells were incubated at room 
temperature for 30 min. The cells were centrifuged, supernatant aspirated and the pellet resuspended 
in 1 ml of 0.1 M Na2B4O7, pH 8.5. Following the centrifugation, the supernatant was removed and the 
cells were resuspended in 0.5 ml of 0.5% Tween/1% BSA/PBS containing 7.5 µl of FITC-conjugated 
anti-BrdU antibody (BioLegend, cat. 364104) and stained overnight at 4 °C in the dark with mixing 
(300 rpm). The cells were centrifuged and the cell pellet was resuspended in 0.5 ml of PBS containing 
5 µg/ml of propidium iodide. The cells were analyzed with Fortessa flow cytometer (Becton Dickinson) 
and BD FACSDIVA software (Becton Dickinson). 
 
Caspase 3/7 activity assay 
Caspase 3/7 activity was measured using Caspase-Glo 3/7 Assay (Promega). U-2 OS and SJSA-
1 cells were seeded on white 96-wells plates and treated with RG7388, (R)-5a, (R)-6a or DMSO for 
24 or 48 hours. Staurosporine, a potent inducer of cell apoptosis, was used as a positive control. 
Next, the plates were equilibrated to room temperature and Caspase-Glo 3/7 Reagent was added 
directly to the wells. The plates were shaken and kept in the dark at room temperature for 1 h. 
Luminescence was measured with Infinite 200 microplate reader. 
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SUPPORTING INFORMATION 
 
Table S1. Optical rotation of the two enantiomers of compounds 5 and 6. 
Table S2. The results of the evaluation of inhibitory activity of compounds (R)-6a and (R)-5a 
towards MDM2/MDMX-p53 complex. 
Table S3. X-ray data collection and structure refinement statistics. 
 
Figure S1. Analytical and preparative chiral separation of (5) via Supercritical Fluid 
Chromatography (SFC). 
Figure S2.  Titration HSQC-based experiment of the 
15
N-labeled MDM2 with (R)-6a. 
Figure S3.  Titration HSQC-based experiment of the 
15
N-labeled MDM2 with (S)-6b. 
Figure S4.  Titration HSQC-based experiment of the 
15





 indole Trp region of 
1
H NMR spectra of the MDM2-p53 complex. 
Figure S6. Crystal structure of compound (R)-6a with Mdm2 (18-125) with electron density 
map. 
Figure S7. (R)-5a induces cell cycle arrest in p53
wt
 SJSA-1, but not in p53
-/-







Table 1. The summary of activities of the trifluoro-substituted compounds. FP – fluorescence 



























(R)-5a 0.4 <1 µM 3.0±2.1  active selective 
(S)-5b 16.7 12.5±3.9 7.7±1.6  not active not selective 






(R)-6a 0.1 <1 µM 7.0±2.1  not active not selective 
(S)-6b 0.28 <1 µM 1.3±0.5  not active not selective 
 
* 
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Figure 1. Reactions and conditions for the synthesis of trifluoro-substituted indole-based 
antagonists. (a) rt, MeOH (1.0 M), 2 d, 76% yield; (b) SFC chiral separation; (c) LiOH, EtOH-H2O, rt, 















Figure 2. (R)-5a interacts with MDM2 protein. Titration HSQC-based experiment of the 
15
N-labeled 
MDM2 with (R)-5a: reference MDM2 – red; MDM2:(R)-5a ratio 3:2 – blue; MDM2:(R)-5a ratio 5:1 – 
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Figure 3. The binding mode of (R)-6a in the hydrophobic pocket of MDM2. (A,B) Stereoview of 
(R)-6a in complex with MDM2 (residues 18-125) – cartoon and surface representation. Inhibitor 
shown as green sticks, MDM2 shown in grey, waters showed as red spheres; (C) Comparison to p53 
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Figure 4. Details of the interaction between (R)-6a and MDM2. (A) Stereoview presenting the π-
stacking with His-96 (shown as red dashed lines) and the residues involved in the hydrophobic 
interactions (shown as grey sticks). Inhibitor shown as yellow sticks, MDM2 shown as grey cartoon; 
(B) Stereoview presenting the hydrogen bonds (shown as black dashed lines) between (R)-6a and 
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Figure 5. The biological activity of (R)-5a, (S)-5b, (R)-6a and (S)-6b compounds. (A,B) Western 
blot analysis of the expression of p53, p21 and Mdm2 in U-2 OS cells following the treatment with the 
indicated compounds. DMSO-treated cells served as a control (marked with “-“). (C) The expression 
of p53-target genes (MDM2 and CDKN1A) and the gene encoding p53 protein (TP53). U-2 OS cells 
were treated with 10 µM of the compound (R)-5a or 5 µM RG7388 for 6 hours. DMSO was used as a 
control. The expression of genes was quantified by real-time PCR with the use of Taq-Man probes. 
The results show mean+SEM values from three experiments, each normalized to GAPDH expression. 
The statistical significance was evaluated using a t-test: *** p<0.05, *** p<0.01, *** p<0.001. (D) To 




) and SAOS-2 (p53
del
) 
cells were treated with the indicated concentrations of the tested compounds and cultured for 5 days. 
The graph shows cell viability normalized to DMSO-treated control cell. (E) Cell cycle analysis of U-2 
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hours with BrdU pulse-labeling for the last 1 hour of the treatment. The cells were stained with FITC-
conjugated anti-BrdU antibody and propidium iodide (PI). The percentages of the cells in the S-phase 
are given on the plots. (F) Caspase 3/7 activity assay. SJSA-1 and U-2 OS cells were treated with the 
indicated concentrations of RG7388, (R)-5a, (R)-6a or DMSO for 24 or 48 hours. Staurosporine, a 
potent inducer of cell apoptosis, was used as a positive control. The results show mean+SEM values 
from three experiments, each normalized to DMSO-treated control cells. The statistical significance 
was evaluated using a t-test: *** p<0.05, *** p<0.01, *** p<0.001. 
 
 
 
